Follow-Up of Venom Immunotherapy on Flow Cytometry and Definition of a Protective Index.
BACKGROUND
A major problem of venom-specific immunotherapy (VIT) is the absence of reliable parameters for deciding treatment discontinuation.


OBJECTIVE
Intracutaneous tests (ICTs), the basophil activation test (BAT), specific IgEs (sIgEs) and blocking factor (BF) activity were measured during VIT. We made an evaluation by means of a protective index (PI) including ICT, BAT and BF values.


METHODS
A population of 45 patients who had experienced a systemic reaction after an insect sting were tested before VIT (T0), at 1 week (T1w), at 10 weeks (T10w) and at 21 weeks (T21w), and, for a subgroup of 17 patients, at 3-5 years (T3-5y). Basophil activation (expressed in % CD63 and in the area under the curve) and BF activity were measured by flow cytometry using the CCR3/CD63 protocol.


RESULTS
The first 21 weeks of follow-up showed no significant variation in the ICT, sIgE and BAT measurements, except for BAT, by eliminating weak negative anti-IgE responses. In these conditions, the decrease in basophil activation was significant at T10w (p = 0.009) and T21w (p = 0.009). Increased BF activity was also significant at T10w (p = 0.008) and T21w (p = 0.002). The PI threshold calculated from the mean ± 3 standard errors (SE) was 64.8 (14.7 ± 16.7, n = 25) at T0. PI increase was significant at T3-5y (3,430 ± 6,282; p < 0.001).


CONCLUSIONS
VIT induced a significant decrease in ICT values and basophil activation, along with an increase in serum BF activity, significant after 10 weeks of VIT. Evaluated in a larger population, the PI could represent a new tool for the clinico-biological follow-up of VIT efficacy.
Immunology Laboratory, Hôpital Dupuytren, Limoges, France.
Jean
J
Sainte-Laudy
François
F
Touraine
Delphine
D
Cluzan
François
F
Belle Moudourou
D000328:Adult; D000368:Aged; D001491:Basophils / Q000276:immunology / Q000378:metabolism; D003888:Desensitization, Immunologic / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D016130:Immunophenotyping; D007299:Insect Bites and Stings / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012882:Skin Tests; D016896:Treatment Outcome; D014688:Venoms / Q000008:administration & dosage / Q000276:immunology*; D055815:Young Adult
D014688:Venoms; D007073:Immunoglobulin E